AKT1 and ovarian cancer: Luo’s team designed a self-assembling nanoparticle (VE-DDP-Pro) that releases VE-DDP and employed both integrin αvβ3 and integrin α5β1 to modulate the AKT/mTOR/MMP-2/laminin and AKT/mTOR/EMT signaling pathways; furthermore, the knockdown of MMP-2 inhibited VEGF release, simultaneously having effects against both VM areas and EDVs, thus greatly improving the efficacy of cisplatin in ovarian cancer [71].